Lip and oral-cavity cancer starts in the lips or tissues inside the mouth, most often as squamous-cell carcinoma. A persistent sore, patch or lump needs dental or medical assessment; appearance alone cannot diagnose cancer. Confidence is high in the anatomy and biopsy distinction. Treatment depends on the tissue diagnosis, exact site, extent and effects on eating, speech and appearance. NHS definition.
- The front of the tongue belongs to the oral cavity; its base and the tonsils belong to the oropharynx.
- A nonhealing sore, unexplained lump or persistent red or white patch deserves assessment, even without tobacco exposure.
- Biopsy establishes what a lesion is; imaging and pathology then help assess extent.
- Surgery, reconstruction, neck-node assessment and selected radiation or systemic care have different roles.
- Dental preparation, swallowing support and nutrition planning are part of cancer care, not optional cosmetic extras.
Table of contents
- Evidence summary
- What counts as lip and oral-cavity cancer
- Risk factors, HPV and prevention boundaries
- Symptoms: sores, patches, lumps and changed function
- Examination, biopsy and specialist staging
- Surgery, neck nodes, reconstruction and radiation
- Systemic medicines: selected roles and current eligibility
- Mouth care, swallowing, nutrition and treatment safety
- When breathing problems need emergency care
- Supplements, restrictive diets and follow-up
- Human research, financial limits and rarer diseases
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Which mouth site and tissue? | Actual NCI professional and patient PDQ plus national NHS anatomy. | PDQ named reviewers’ project support and incomplete declarations traced; exact page/trial payments unclosed. | Mucosal oral SCC, external-lip skin cancer and oropharyngeal disease need distinct classification. |
| Biopsy and stage | Selected NHS diagnostic pathway and NCI professional staging account. | Public education and reviewer-linked context; original diagnostic-study finances not fully closed. | Tissue, imaging and specialist interpretation answer different questions; no home staging. |
| Treatment roles and medicine eligibility | NHS broad treatment, NCI team context and June 2025 FDA decision. | Mixed reviewer research support; manufacturer-applicant outcomes Tier 4/D and excluded. | Attributed care roles and dated US status only; no independent product-effect estimate or personal regimen. |
| Supportive care and supplements | NCI mouth/radiation, nutrition and NHS safety bodies. | Exact contributors and underlying trials unclosed; dated sources explicitly limited. | Function and adequate nutrition need clinician-led support; laboratory activity does not establish a supplement cure. |
What counts as lip and oral-cavity cancer
The oral cavity includes the front tongue, gums, inner cheeks, mouth floor and hard palate. Most cancers are squamous-cell carcinomas. NCI anatomical framework.
A minor salivary-gland cancer can occur in the same region but has a different histology. Surface-confined and invasive lesions are different findings. The dry external lip is excluded from oral-cavity staging; a skin cancer there needs cutaneous assessment. NCI professional scope.
This guide covers the common mucosal squamous-cancer framework. It does not treat every salivary tumour, lip-skin cancer, rare histology or precancerous lesion as the same disease. Ask which tissue and surface the pathology report actually identifies.
Risk factors, HPV and prevention boundaries
Tobacco, alcohol and betel quid are oral-cancer risks. HPV-associated tonsil and tongue-base biology should not automatically be transferred to mouth-lining cancer. NCI site-specific risk explanation.
Ultraviolet exposure can affect the external lip; immune suppression and abnormal mouth lesions also matter. A risk factor does not prove that a lesion is cancer, and people without an obvious exposure can still develop it. Ask for help stopping tobacco and reducing alcohol. Sun protection belongs to external-lip prevention, not an assurance that an existing mucosal lesion is harmless. Do not stop an immune medicine because of a risk list; the prescribing clinician must weigh its benefits and alternatives. NHS dated risk context.
Symptoms: sores, patches, lumps and changed function
Arrange assessment for an ulcer that does not heal, an unexplained lip or mouth lump, a persistent red or white patch, mouth pain, or a neck lump. Problems swallowing or speaking, continuing hoarseness and unexplained weight loss are also relevant. Many noncancerous conditions cause these symptoms, so neither a photograph nor a symptom checklist establishes the diagnosis. NHS advises checking an ulcer lasting over three weeks; this is not permission to delay a worsening lesion or swallowing problem. NHS dated symptom guidance.
Unexplained numbness, bleeding, jaw swelling, loose teeth or a denture that suddenly fits differently can also be clues. Some cancers are noticed during a dental examination before symptoms are apparent. An apparently normal examination at one time does not settle a later new lesion. NCI patient signs.
Describe the problem rather than blaming yourself for an exposure. The purpose of referral is to establish what is happening and whether tissue testing is needed.
Examination, biopsy and specialist staging
A dentist or doctor examines the mouth and neck and may refer an abnormal area to a specialist. A biopsy removes tissue for laboratory examination. If cancer is confirmed, selected CT, MRI, ultrasound or other tests help assess its location and spread; everyone does not need every listed scan. Ask what was sampled, how the result will reach you and who arranges the next step. If the expected result or appointment has not arrived, contact the service rather than assuming silence means reassurance. NHS diagnostic pathway.
Pathology helps distinguish tissue type and invasion. Oral-cavity staging considers more than a visible lesion’s width: depth of invasion, neck-node involvement, spread beyond a node and distant disease can matter. Depth of invasion and tumour thickness are not interchangeable measurements. The specialist combines examination, pathology and imaging; a home ruler or an isolated scan finding cannot assign the stage. NCI professional staging framework.
For a second opinion, share the pathology material and scans as well as the report. Ask which uncertainties remain and whether further sampling would change the proposed care.
Surgery, neck nodes, reconstruction and radiation
Surgery is a major treatment for mouth cancer. The operation may remove the tumour and selected surrounding tissue, involved jaw tissue or neck lymph nodes. Reconstruction can use tissue from elsewhere in the body to repair an area after removal. The extent depends on the actual cancer; a list of procedures is not a plan for every patient. Radiation may be used in selected settings alone, after surgery, alongside medicines or for symptom relief. Selected care can also involve chemotherapy, targeted medicines or immunotherapy, according to the cancer setting. Ask how the proposed approach affects chewing, speech, swallowing, appearance and recovery. NHS dated treatment framework.
A specialist head-and-neck team can include surgeons, radiation and medical oncologists, dentists, dietitians, speech therapists, rehabilitation clinicians and psychological support. The plan should explain the treatment goal and trade-offs, not simply name an operation. Selected surgery may also require reconstruction or a dental prosthesis. NCI patient care-team framework.
Broad care roles are supported by clinical education sources. This review does not independently rank operations, radiation techniques or medicine brands, or adopt numerical cure claims from unclosed underlying trials.
Systemic medicines: selected roles and current eligibility
The FDA’s June 12, 2025 decision includes perioperative pembrolizumab for selected adults with resectable locally advanced head-and-neck squamous cancer meeting its PD-L1 criterion. This is selected US status; individual suitability and local access require specialist review. FDA selected regulatory status.
Manufacturer-applicant outcomes are excluded from the independent verdict. Ask the treatment goal and whether current local eligibility fits the diagnosis; an older medicine list is not a complete current menu.
Mouth care, swallowing, nutrition and treatment safety
Treatment can cause dry mouth, sores, taste changes, pain, infections and tooth decay. Before treatment, arrange dental coordination and tell the dentist the intended cancer therapy. Mouth pain that prevents eating, drinking or sleeping needs contact with the team. Swallowing impairment requires an individually safe intake plan. Mouth rinses, pain medicines and dental procedures need a plan fitted to treatment and bleeding risk, rather than a universal online recipe. NCI dated mouth-care context.
Radiation can affect healthy tissue as well as cancer. Effects depend on the treated field and may include fatigue, skin changes, mouth or swallowing problems and reduced thyroid function. Some effects persist or develop later. Ask which problems require immediate contact and which need planned monitoring after treatment. Do not assume every new symptom is an unavoidable radiation effect. NCI radiation safety context.
Coughing or choking with meals, food sticking, a wet voice after swallowing or breathlessness after eating needs urgent clinical advice. Swallowing difficulty can lead to dehydration, weight loss or chest infections. A speech-language therapist and dietitian can assess safe eating or alternative support; do not improvise a thickener or feeding-tube plan. NHS swallowing warning.
When breathing problems need emergency care
Severe difficulty breathing, choking, inability to get words out, blue or grey lips or skin, or sudden confusion requires emergency help through the local emergency service. Do not drive yourself. These signs can have several causes; do not wait to identify whether cancer or treatment is responsible. NHS emergency breathing guidance.
Keep the oncology team’s urgent contact details available, including the out-of-hours route. Explain any new difficulty taking prescribed medicines or maintaining intake promptly. A dental appointment or routine follow-up is not a substitute for emergency assessment when breathing is severely impaired. Caregivers should know whom to contact and bring the current treatment and medicine list.
Supplements, restrictive diets and follow-up
No diet trend, herb, vitamin or supplement has been proved to cure cancer, slow it or prevent its return in the NCI account reviewed here. Products can change how cancer medicines work. Give the pharmacist ingredient labels and a complete medicine list before adding an extract, high-dose vitamin or complementary product. Treating a documented deficiency is different from claiming an anticancer effect. A restrictive diet can make adequate intake harder when chewing and swallowing already cause difficulty. Nutritional and symptom support should serve the clinical plan rather than replace it. NCI nutrition and supplement boundaries.
After treatment, keep a survivorship plan with pathology, operation, radiation and medicine details. It should identify follow-up responsibility, late-effect care and symptoms to report between visits. Share the plan with primary and dental care so new problems are assessed in the context of prior treatment. A new symptom should not simply wait for the next scheduled scan. NCI follow-up planning.
Human research, financial limits and rarer diseases
Cancer-treatment trials and supportive-care studies ask different questions. If considering a study, ask about its purpose, comparison care, patient outcomes, harms, costs and funding. Participation is research, not a promise that an experimental approach will help. A laboratory effect on a mouth-cancer cell is not proof of safe benefit in a person. NCI trial categories.
The source map distinguishes agency budgets, reviewer research roles, manufacturer drug supply and regulatory status. A public summary cannot make sponsored underlying trial results independent. Rare oral histologies, external-lip skin cancers, precancerous lesions and distinct throat sites require their own scope assessment; an overview does not complete every subtype.
Funding and source roles
Research funding at a glance
31 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI lip/oral-cavity professional PDQ | PDQ policy; Bonetti supplier-linked research, Truong incomplete declaration. Full page/trial payments unclosed. | United States; NCI, Bethesda, Maryland; international reviewers. | Tier 3 reviewer-linked research; incomplete interests. | C, provisional; named leads/derivation checked. Editorial review does not clear sponsored trials. |
| NCI lip/oral-cavity patient PDQ | PDQ policy; Bonetti supplier-linked research, Truong incomplete declaration. Full page/trial payments unclosed. | United States; NCI, Bethesda, Maryland; international reviewers. | Tier 3 reviewer-linked research; incomplete interests. | C, provisional; named leads/derivation checked. Editorial review does not clear sponsored trials. |
| NHS mouth-cancer definition | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS mouth-cancer symptoms | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS mouth-cancer causes | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS mouth-cancer tests | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS mouth-cancer treatment | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NCI head-and-neck cancer fact sheet | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI native mouth and throat side effects | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | C, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI radiation side effects | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI diets and supplements | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI follow-up medical care | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI clinical-trial explanation | Public budget and gifts; page/contributor/study payments unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NHS swallowing-problem safety | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS severe breathing warning | National policy; contributor/study payments unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| Andrea Bonetti current own biography and clinical-service page | Own biography identifies PDQ membership, Pederzoli clinical-trial/accreditation consultancy since 2024 and current responsibility for EORTC 2129 TREATctDNA. The site offers private oncology consultations. Exact remuneration and page allocation are not public here. | Italy; oncology biography identifies Pederzoli Hospital and former Mater Salutis, Legnago roles. Complete service/entity income and beneficial ownership unclosed. | Tier 4 private clinical-service self-report; financial identity only. | D for commercial independence — actual own body read. Useful identity evidence, but self-presentation and service-sales incentives remain; no clinical outcomes adopted. |
| EORTC and Menarini TREATctDNA announcement, October 19, 2023 | The joint announcement says Menarini and subsidiary Stemline will provide elacestrant for EORTC 2129. Bonetti’s separate current biography identifies his role in that project. Stemline is described as wholly owned by Menarini. This does not document personal fees or PDQ payments. | Belgium and Italy; announcement dateline Brussels/Florence. Complete trial contracts, assay support and supplier/manufacturing jurisdictions unclosed. | Tier 4 manufacturer-supplied trial; excluded independent efficacy. | D for independence — direct product-seller support is documented. Financial-role evidence only; no trial benefit, response, dose or medicine recommendation adopted. |
| EORTC institutional funding model | Actual own page lists institutional, corporate and private donations; study/service fees; industry-funded trials; EU grants and other restricted/unrestricted routes. It states there is no direct government subsidy. Its chart and narrative periods differ; no current complete audited ledger inferred. | Belgium; EORTC is established under Belgian law. Headquarters in the separate contact row. | Tier 3 institution with mixed commercial and noncommercial funding. | B, provisional — explicit routes improve transparency; fundraising incentives, dated components and exact project/reviewer allocation gaps remain. |
| EORTC current institutional contact | Own institutional identity source; mixed revenue routes documented separately. | Belgium; Avenue Emmanuel Mounier 83/11, 1200 Brussels. International clinical research. | Tier 3 institutional identity self-report. | B, provisional — actual address read; location does not establish independent evidence or identify all trial sites. |
| Menarini current headquarters and company registration | Own page identifies A. Menarini Industrie Farmaceutiche Riunite SRL and Florence company registration. The separate EORTC announcement establishes its product-supply route. Full beneficial ownership, trial amounts and individual remuneration not verified. | Italy; Via Sette Santi 1, 50131 Firenze, Florence. Headquarters is not the complete manufacturing chain. | Tier 4 therapeutic-product supplier self-report. | D for independence — direct seller interests; identity evidence only. Exact backers, subcontractors and financial allocations remain unclosed. |
| Minh Tam Truong ASTRO 2024 presenter disclosure | Actual page identifies Boston Medical Center/Boston University employment and no ownership/leadership interests. The compensation field contains an incomplete placeholder and is not interpreted as no compensation. Full income and PDQ payments remain unclosed. | United States; Boston, Massachusetts affiliations. Exact activity revenues and other backer jurisdictions unclosed. | Tier 3 incomplete author financial self-report. | C, provisional — actual identity and field contents read; malformed compensation disclosure prevents financial clearance. No event treatment claims adopted. |
| ASTRO 2022 head-and-neck committee disclosures | Actual three-page original lists Truong’s Boston Medical Center and Veterans Affairs roles plus American Board of Radiology travel expenses. This is scoped to the 2022 activity and previous year; other faculty’s commercial interests are not attributed to her. | United States; named Boston affiliations. Full ASTRO/ABR revenue, travel amounts and present reviewer income not traced. | Tier 3 dated activity financial self-report. | B, provisional — explicit historical disclosure assists provenance; it does not clear later compensation or assign payment to a May 2025 PDQ page. |
| FDA June 12, 2025 head-and-neck perioperative approval | Public/user-fee routes; Merck applicant data Tier 4/D, independent efficacy excluded. | United States FDA jurisdiction; Silver Spring, Maryland. | Tier 2 dated regulatory status only. | B, provisional; actual decision. Eligibility/local-access gaps; approval does not clear applicant trials. |
| Merck second-quarter 2026 financial results | Actual August 4, 2026 report documents pharmaceutical/product sales, including Keytruda/Keytruda Qlex, collaboration and investor routes. Development transactions include licensing and a Blackstone funding agreement; no exact head-and-neck trial allocation inferred. | United States; Merck & Co., Inc., Rahway, New Jersey, known as MSD outside the US/Canada. Separate from German Merck KGaA. | Tier 4 therapeutic-product seller financial self-report. | D for independence — sales and investor incentives are direct. Selected financial routes only; no company treatment outcomes adopted and complete controlling interests remain unclosed. |
| Merck August 4, 2026 SEC corporate identity filing | Registrant filing identifies New Jersey incorporation, NYSE common stock and debt securities. Product revenues are in the separate company financial row; complete beneficial ownership and application spending not audited here. | United States; 126 East Lincoln Avenue, Rahway, New Jersey 07065. Executive office is not every manufacturing site. | Tier 4 manufacturer identity disclosure held by a regulator. | D for source independence — repository hosting does not change issuer interests. Statutory disclosure helps identity checking, with ownership and site-chain limits. |
| FDA FY2026 operating plan | Actual five-page plan distinguishes public budget authority and regulated-industry user fees, including drugs/biologics. No exact application or page fee assigned. | United States; federal FDA/HHS, Silver Spring, Maryland. | Tier 3 regulator financial self-report. | B, provisional — fiscal transparency and statutory accountability; fee routes, policy priorities and page allocation remain. |
| FDA visitor and headquarters information | Official institutional location self-report; public/fee routes in separate operating-plan profile. | United States; White Oak campus, Silver Spring, Maryland. | Tier 3 regulator identity self-report. | B, provisional — actual body read; regulator location does not identify a drug manufacturing site. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
Frequently asked questions
Is cancer at the tongue base the same as cancer at the front? No. The front belongs to the oral cavity; the base belongs to the oropharynx, where HPV-related biology and staging differ. NCI anatomy.
Does a white patch prove cancer? No. A persistent patch needs examination and sometimes tissue sampling; appearance alone cannot establish invasion. NHS assessment.
Should a nonsmoker ignore a persistent mouth ulcer? No. An unexplained persistent sore or lump deserves assessment regardless of known exposure. NHS symptoms.
Does the FDA decision mean everyone needs immunotherapy before surgery? No. It is a selected biomarker- and disease-setting approval. Individual suitability and local access need specialist review. FDA status.
Sources and funding notes
Selected original clinical and financial bodies, patient derivation and named professional leads were checked. NHS mouth and swallowing sources have passed scheduled review dates; dated NCI mouth guidance supports bounded care. The funding map retains the separately documented research-support chain and incomplete declarations without page-payment inference. Manufacturer trial efficacy is excluded. No personal dose, stage algorithm, scan interval, mouth-care recipe or numerical outcome is adopted. Rare subtype-specific care and complete page/trial financial allocations remain unassessed.
- NCI lip/oral-cavity professional PDQ — Selected anatomy, staging and named lead attribution.
- NCI lip/oral-cavity patient PDQ — Symptoms and multidisciplinary care; professional derivation verified.
- NHS mouth-cancer definition — Direct-answer scope.
- NHS mouth-cancer symptoms — Persistent changes and assessment.
- NHS mouth-cancer causes — Risk context only.
- NHS mouth-cancer tests — Biopsy and selected staging tests.
- NHS mouth-cancer treatment — Broad local treatment and reconstruction roles.
- NCI head-and-neck cancer fact sheet — Anatomy, risk and rehabilitation context; no quantitative outcomes.
- NCI native mouth and throat side effects — Dental coordination and functional problems only; dated, no home rinse or intake protocol.
- NCI radiation side effects — Treatment-field and late-effect context.
- NCI diets and supplements — Unproved cure and treatment-compatibility boundaries.
- NCI follow-up medical care — Individual survivorship planning.
- NCI clinical-trial explanation — Human research categories and informed questions, not treatment benefit.
- NHS swallowing-problem safety — Selected urgent warning only; no diagnostic self-test or numerical protocol.
- NHS severe breathing warning — Selected urgent warning only; no diagnostic self-test or numerical protocol.
- Andrea Bonetti current own biography and clinical-service page — Reviewer identity, clinical employment and named research role only.
- EORTC and Menarini TREATctDNA announcement, October 19, 2023 — Dated trial drug-supply provenance only; breast-cancer treatment outcomes not used.
- EORTC institutional funding model — Research-organisation revenue routes only.
- EORTC current institutional contact — Research-organisation headquarters only.
- Menarini current headquarters and company registration — Named drug-provider corporate identity only.
- Minh Tam Truong ASTRO 2024 presenter disclosure — Dated reviewer identity and activity-specific declaration only.
- ASTRO 2022 head-and-neck committee disclosures — Historical, activity-specific Truong financial declaration only.
- FDA June 12, 2025 head-and-neck perioperative approval — Selected US regulatory status only; applicant trial efficacy excluded.
- Merck second-quarter 2026 financial results — Product-seller revenue and incentives only.
- Merck August 4, 2026 SEC corporate identity filing — Corporate registration and principal executive office only.
- FDA FY2026 operating plan — Actual regulator funding route only.
- FDA visitor and headquarters information — Regulator location only.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.